Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of frontotemporal dementia

Background Diagnosis of Frontotemporal dementia (FTD) and its specific underlying neuropathologies (frontotemporal lobar degeneration; FTLD-Tau and FTLD-TDP) are challenging, and thus, fluid biomarkers are needed to improve diagnostic accuracy. Methods We used proximity extension assays to analyze 6...

Descripción completa

Detalles Bibliográficos
Autores: Hok-A-Hin, YS, Vermunt, L, Peeters, CFW, van der Ende, EL, de Boer, SCM, Meeter, LH, de Houwer, J, Seelaar, H, van Swieten, JC, Hu, WT, Lleó, A, Alcolea, D, Engelborghs, S, Sieben, A, Chen-Plotkin, A, Irwin, DJ, van der Flier, WM, Pijnenburg, YAL, Teunissen, CE, del Campo, M
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p20125
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20125
Access Level:acceso abierto
Palabra clave:FTD
FTLD
Tau
TDP43
Biomarkers
Proteomics
CSF
id ES_0bdc91b22c98d53c5bcfb65d7f5fb2db
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p20125
network_acronym_str ES
network_name_str España
repository_id_str
spelling Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of frontotemporal dementiaHok-A-Hin, YSVermunt, LPeeters, CFWvan der Ende, ELde Boer, SCMMeeter, LHde Houwer, JSeelaar, Hvan Swieten, JCHu, WTLleó, AAlcolea, DEngelborghs, SSieben, AChen-Plotkin, AIrwin, DJvan der Flier, WMPijnenburg, YALTeunissen, CEdel Campo, MFTDFTLDTauTDP43BiomarkersProteomicsCSFBackground Diagnosis of Frontotemporal dementia (FTD) and its specific underlying neuropathologies (frontotemporal lobar degeneration; FTLD-Tau and FTLD-TDP) are challenging, and thus, fluid biomarkers are needed to improve diagnostic accuracy. Methods We used proximity extension assays to analyze 665 proteins in cerebrospinal fluid (CSF) samples from a multicenter cohort, which included patients with FTD (n = 189), Alzheimer's Disease dementia (AD; n = 232), and cognitively unimpaired individuals (n = 196). In a subset, FTLD neuropathology was determined based on phenotype or genotype (FTLD-Tau = 87 and FTLD-TDP = 67). Differences in protein expression profiles were analyzed using nested linear models. Penalized generalized linear modeling was used to identify classification protein panels, which were translated to custom multiplex assays and validated in two clinical cohorts (cohort 1: n = 161; cohort 2: n = 162), one autopsy-confirmed cohort (n = 100), and one genetic cohort (n = 55). Results Forty-three proteins were differentially regulated in FTD compared to controls and AD, reflecting axon development, regulation of synapse assembly, and cell-cell adhesion mediator activity pathways. Classification analysis identified a 14- and 13-CSF protein panel that discriminated FTD from controls (FTD diagnostic panel, AUC: 0.96) or AD (FTD differential diagnostic panel, AUC: 0.91). Custom multiplex panels confirmed the strong discriminative performancen between FTD and controls (AUCs > 0.96) and between FTD and AD (AUCs > 0.88) across three validation cohorts, including one with autopsy confirmation (AUCs > 0.90). Validation in genetic FTD (including C9orf72, GRN, and MAPT mutation carriers) revealed high accuracy of the FTD diagnostic panel in identifying both the presymptomatic (AUCs > 0.95) and symptomatic (AUC: 1) stages. Six proteins were differentially regulated between FTLD-TDP and FTLD-Tau. However, a reproducible classification model could not be generated (AUC: 0.80). Conclusions Overall, this study introduces novel FTD-specific biomarker panels with potential use in diagnostic settings.BMC2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20125Molecular NeurodegenerationISSN: 17501326reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p201252026-06-14T12:41:47Z
dc.title.none.fl_str_mv Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of frontotemporal dementia
title Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of frontotemporal dementia
spellingShingle Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of frontotemporal dementia
Hok-A-Hin, YS
FTD
FTLD
Tau
TDP43
Biomarkers
Proteomics
CSF
title_short Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of frontotemporal dementia
title_full Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of frontotemporal dementia
title_fullStr Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of frontotemporal dementia
title_full_unstemmed Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of frontotemporal dementia
title_sort Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of frontotemporal dementia
dc.creator.none.fl_str_mv Hok-A-Hin, YS
Vermunt, L
Peeters, CFW
van der Ende, EL
de Boer, SCM
Meeter, LH
de Houwer, J
Seelaar, H
van Swieten, JC
Hu, WT
Lleó, A
Alcolea, D
Engelborghs, S
Sieben, A
Chen-Plotkin, A
Irwin, DJ
van der Flier, WM
Pijnenburg, YAL
Teunissen, CE
del Campo, M
author Hok-A-Hin, YS
author_facet Hok-A-Hin, YS
Vermunt, L
Peeters, CFW
van der Ende, EL
de Boer, SCM
Meeter, LH
de Houwer, J
Seelaar, H
van Swieten, JC
Hu, WT
Lleó, A
Alcolea, D
Engelborghs, S
Sieben, A
Chen-Plotkin, A
Irwin, DJ
van der Flier, WM
Pijnenburg, YAL
Teunissen, CE
del Campo, M
author_role author
author2 Vermunt, L
Peeters, CFW
van der Ende, EL
de Boer, SCM
Meeter, LH
de Houwer, J
Seelaar, H
van Swieten, JC
Hu, WT
Lleó, A
Alcolea, D
Engelborghs, S
Sieben, A
Chen-Plotkin, A
Irwin, DJ
van der Flier, WM
Pijnenburg, YAL
Teunissen, CE
del Campo, M
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv FTD
FTLD
Tau
TDP43
Biomarkers
Proteomics
CSF
topic FTD
FTLD
Tau
TDP43
Biomarkers
Proteomics
CSF
description Background Diagnosis of Frontotemporal dementia (FTD) and its specific underlying neuropathologies (frontotemporal lobar degeneration; FTLD-Tau and FTLD-TDP) are challenging, and thus, fluid biomarkers are needed to improve diagnostic accuracy. Methods We used proximity extension assays to analyze 665 proteins in cerebrospinal fluid (CSF) samples from a multicenter cohort, which included patients with FTD (n = 189), Alzheimer's Disease dementia (AD; n = 232), and cognitively unimpaired individuals (n = 196). In a subset, FTLD neuropathology was determined based on phenotype or genotype (FTLD-Tau = 87 and FTLD-TDP = 67). Differences in protein expression profiles were analyzed using nested linear models. Penalized generalized linear modeling was used to identify classification protein panels, which were translated to custom multiplex assays and validated in two clinical cohorts (cohort 1: n = 161; cohort 2: n = 162), one autopsy-confirmed cohort (n = 100), and one genetic cohort (n = 55). Results Forty-three proteins were differentially regulated in FTD compared to controls and AD, reflecting axon development, regulation of synapse assembly, and cell-cell adhesion mediator activity pathways. Classification analysis identified a 14- and 13-CSF protein panel that discriminated FTD from controls (FTD diagnostic panel, AUC: 0.96) or AD (FTD differential diagnostic panel, AUC: 0.91). Custom multiplex panels confirmed the strong discriminative performancen between FTD and controls (AUCs > 0.96) and between FTD and AD (AUCs > 0.88) across three validation cohorts, including one with autopsy confirmation (AUCs > 0.90). Validation in genetic FTD (including C9orf72, GRN, and MAPT mutation carriers) revealed high accuracy of the FTD diagnostic panel in identifying both the presymptomatic (AUCs > 0.95) and symptomatic (AUC: 1) stages. Six proteins were differentially regulated between FTLD-TDP and FTLD-Tau. However, a reproducible classification model could not be generated (AUC: 0.80). Conclusions Overall, this study introduces novel FTD-specific biomarker panels with potential use in diagnostic settings.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20125
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20125
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv BMC
publisher.none.fl_str_mv BMC
dc.source.none.fl_str_mv Molecular Neurodegeneration
ISSN: 17501326
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403251699351552
score 15.812455

Similares en LA Referencia